Journal of thoracic disease · 2026
Efficacy and safety of time-of-day infusion of pemetrexed plus platinum for patients with advanced non-small cell lung cancer: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hao Meng-Di, Xie Pei, Xu Quan-An, Li Jiang-Jing, Xian Ke-Xin, Xu Xian, Liu Wei-Lu, Zhou Dai-Yan, Wang Zi-Yi, Zeng Xin-Xin, Zhang Xu-Hui
Аннотация
BACKGROUND: Retrospective studies indicate that morning chemotherapy enhances efficacy and reduces side effects in non-small cell lung cancer (NSCLC). However, the role of infusion timing for pemetrexed plus platinum (AP) chronotherapy remains unclear. This study evaluates the impact of AP administration time on efficacy and safety in advanced NSCLC.
METHODS: We retrospectively analyzed 132 advanced NSCLC patients receiving AP chemotherapy at Guangdong Second Provincial General Hospital from 2018 to 2023. Based on previous research, patients were grouped into morning (AM; infusion before 2:00 PM, n=58) and afternoon (PM; n=74) groups. Treatment response was evaluated using the Response Evaluation Criteria in Solid Tumors Criteria V.1.1. The primary endpoint was progression-free survival (PFS), with safety profile serving as the secondary endpoint. All adverse events (AEs) were identified and graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0.
RESULTS: The AM group showed significantly longer PFS than the PM group (24.0 vs. 14.0 months, P=0.04). Subsequent subgroup analysis in the AP cohort favored the AM group across all major subgroups for PFS treatment effect. Furthermore, the analysis of adverse reactions revealed similar incidences of any treatment-emergent adverse events (TEAEs) in both AM and PM (AM 86.21% vs. PM 86.49% in AP cohort), and grade ≥3 TEAEs (AM 31.03% vs. PM 21.62% in AP cohort). The most common AEs were anemia, leukopenia, and neutropenia. Univariate and multivariate analyses indicated that the infusion time of AP chemotherapy (P=0.03) was an independent prognostic factor for NSCLC.
CONCLUSIONS: AP treatment administered in the morning may enhance PFS in advanced NSCLC. This suggests that chrono-chemotherapy (CCT) could potentially enhance the efficacy of individualized chemotherapy in advanced NSCLC.
METHODS: We retrospectively analyzed 132 advanced NSCLC patients receiving AP chemotherapy at Guangdong Second Provincial General Hospital from 2018 to 2023. Based on previous research, patients were grouped into morning (AM; infusion before 2:00 PM, n=58) and afternoon (PM; n=74) groups. Treatment response was evaluated using the Response Evaluation Criteria in Solid Tumors Criteria V.1.1. The primary endpoint was progression-free survival (PFS), with safety profile serving as the secondary endpoint. All adverse events (AEs) were identified and graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0.
RESULTS: The AM group showed significantly longer PFS than the PM group (24.0 vs. 14.0 months, P=0.04). Subsequent subgroup analysis in the AP cohort favored the AM group across all major subgroups for PFS treatment effect. Furthermore, the analysis of adverse reactions revealed similar incidences of any treatment-emergent adverse events (TEAEs) in both AM and PM (AM 86.21% vs. PM 86.49% in AP cohort), and grade ≥3 TEAEs (AM 31.03% vs. PM 21.62% in AP cohort). The most common AEs were anemia, leukopenia, and neutropenia. Univariate and multivariate analyses indicated that the infusion time of AP chemotherapy (P=0.03) was an independent prognostic factor for NSCLC.
CONCLUSIONS: AP treatment administered in the morning may enhance PFS in advanced NSCLC. This suggests that chrono-chemotherapy (CCT) could potentially enhance the efficacy of individualized chemotherapy in advanced NSCLC.